ACAD Q3 2020 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$121M+27.5% YoY

Gross Profit

$116M96.0% margin

Operating Income

-$86M-71.2% margin

Net Income

-$85M-70.2% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$25M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$796M

Total Liabilities

$141M

Stockholders' Equity

$655M

Cash & Equivalents

$452M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$121M	$95M	+27.5%
Gross Profit	$116M	$90M	+28.8%
Operating Income	-$86M	-$45M	-89.1%
Net Income	-$85M	-$42M	-101.7%